6 December 2018 - The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.

There is no doubt that the price of new biologics is astonishingly high, although the industry and payers generally seem accepting of the need to pay for cutting-edge drugs for rare diseases that have no other treatment. There are questions to be asked, however, about why the general public is so negative about the expensive of life-altering treatments. 

Drug pricing is extremely complicated, with the myriad ways in which drug companies, payers and prescription benefits managers interact to set prices, incur rebates, and provide support for payments.

Read BioSpace article